Literature DB >> 23225159

Somatic mutation of PARK2 tumor suppressor gene is not common in common solid cancers.

Eun Mi Je1, Nam Jin Yoo, Sug Hyung Lee.   

Abstract

Recent studies identified that PARK2 gene was a candidate tumor suppressor gene in colorectal cancers and glioblastomas. The aim of this study was identify whether PARK2 somatic mutation is present in other solid tumor as well. In this study, we analyzed the entire coding sequences of human PARK2 gene in gastric, colorectal, breast, lung and prostate carcinoma by single-strand conformation polymorphism (SSCP) and subsequent direct DNA sequencing. We found two missense mutations (p.Ser9Thr and p.Gly450Val) in colon carcinomas (4.3 %), which were not overlapped with the known PARK2 mutations. Our data suggest that somatic mutational events in PARK2 gene may be rare in colorectal, gastric, prostate, breast and lung carcinomas and may not play an important role in the development of these cancers.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23225159     DOI: 10.1007/s12253-012-9591-z

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  14 in total

1.  Parkin mediates proteasome-dependent protein degradation and rupture of the outer mitochondrial membrane.

Authors:  Saori R Yoshii; Chieko Kishi; Naotada Ishihara; Noboru Mizushima
Journal:  J Biol Chem       Date:  2011-03-18       Impact factor: 5.157

2.  Somatic mutations and losses of expression of microRNA regulation-related genes AGO2 and TNRC6A in gastric and colorectal cancers.

Authors:  Min S Kim; Ji E Oh; Yoo R Kim; Sang W Park; Mi R Kang; Sung S Kim; Chang H Ahn; Nam J Yoo; Sug H Lee
Journal:  J Pathol       Date:  2010-06       Impact factor: 7.996

3.  PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas.

Authors:  Jong Woo Lee; Young Hwa Soung; Su Young Kim; Hae Woo Lee; Won Sang Park; Suk Woo Nam; Sang Ho Kim; Jung Young Lee; Nam Jin Yoo; Sug Hyung Lee
Journal:  Oncogene       Date:  2005-02-17       Impact factor: 9.867

4.  Mutational analysis of FOXL2 codon 134 in granulosa cell tumour of ovary and other human cancers.

Authors:  Min Sung Kim; Soo Young Hur; Nam Jin Yoo; Sug Hyung Lee
Journal:  J Pathol       Date:  2010-06       Impact factor: 7.996

5.  PARK2 deletions occur frequently in sporadic colorectal cancer and accelerate adenoma development in Apc mutant mice.

Authors:  George Poulogiannis; Rebecca E McIntyre; Maria Dimitriadi; John R Apps; Catherine H Wilson; Koichi Ichimura; Feijun Luo; Lewis C Cantley; Andrew H Wyllie; David J Adams; Mark J Arends
Journal:  Proc Natl Acad Sci U S A       Date:  2010-08-09       Impact factor: 11.205

6.  Oncogenic NRF2 mutations in squamous cell carcinomas of oesophagus and skin.

Authors:  Yoo Ri Kim; Ji Eun Oh; Min Sung Kim; Mi Ran Kang; Sang Wook Park; Ji Youn Han; Hyeon Seok Eom; Nam Jin Yoo; Sug Hyung Lee
Journal:  J Pathol       Date:  2010-03       Impact factor: 7.996

7.  Alterations of the tumor suppressor gene Parkin in non-small cell lung cancer.

Authors:  Maria Cristina Picchio; Eric Santos Martin; Rossano Cesari; George Adrian Calin; Sai Yendamuri; Tamotsu Kuroki; Francesca Pentimalli; Manuela Sarti; Kristine Yoder; Larry R Kaiser; Richard Fishel; Carlo Maria Croce
Journal:  Clin Cancer Res       Date:  2004-04-15       Impact factor: 12.531

8.  Somatic mutations of the Parkinson's disease-associated gene PARK2 in glioblastoma and other human malignancies.

Authors:  Selvaraju Veeriah; Barry S Taylor; Shasha Meng; Fang Fang; Emrullah Yilmaz; Igor Vivanco; Manickam Janakiraman; Nikolaus Schultz; Aphrothiti J Hanrahan; William Pao; Marc Ladanyi; Chris Sander; Adriana Heguy; Eric C Holland; Philip B Paty; Paul S Mischel; Linda Liau; Timothy F Cloughesy; Ingo K Mellinghoff; David B Solit; Timothy A Chan
Journal:  Nat Genet       Date:  2009-11-29       Impact factor: 38.330

9.  Parkin as a tumor suppressor gene for hepatocellular carcinoma.

Authors:  M Fujiwara; H Marusawa; H-Q Wang; A Iwai; K Ikeuchi; Y Imai; A Kataoka; N Nukina; R Takahashi; T Chiba
Journal:  Oncogene       Date:  2008-06-23       Impact factor: 9.867

Review 10.  How does parkin ligate ubiquitin to Parkinson's disease?

Authors:  Philipp J Kahle; Christian Haass
Journal:  EMBO Rep       Date:  2004-07       Impact factor: 8.807

View more
  7 in total

1.  Implication of alterations in Parkin gene among North Indian patients with colorectal cancer.

Authors:  Raj Ranjan Tiwari; Khushnuma Wahabi; Ahmad Perwez; Zafar Iqbal Bhat; Syed Shamimul Hasan; Sundeep Singh Saluja; Moshahid Alam Rizvi
Journal:  Turk J Gastroenterol       Date:  2020-03       Impact factor: 1.852

2.  Two Distinct Categories of Focal Deletions in Cancer Genomes.

Authors:  Megha Rajaram; Jianping Zhang; Tim Wang; Jinyu Li; Cem Kuscu; Huan Qi; Mamoru Kato; Vladimir Grubor; Robert J Weil; Aslaug Helland; Anne-Lise Borrenson-Dale; Kathleen R Cho; Douglas A Levine; Alan N Houghton; Jedd D Wolchok; Lois Myeroff; Sanford D Markowitz; Scott W Lowe; Michael Zhang; Alex Krasnitz; Robert Lucito; David Mu; R Scott Powers
Journal:  PLoS One       Date:  2013-06-21       Impact factor: 3.240

3.  Parkin targets HIF-1α for ubiquitination and degradation to inhibit breast tumor progression.

Authors:  Juan Liu; Cen Zhang; Yuhan Zhao; Xuetian Yue; Hao Wu; Shan Huang; James Chen; Kyle Tomsky; Haiyang Xie; Christen A Khella; Michael L Gatza; Dajing Xia; Jimin Gao; Eileen White; Bruce G Haffty; Wenwei Hu; Zhaohui Feng
Journal:  Nat Commun       Date:  2017-11-28       Impact factor: 14.919

4.  PARK2 inhibits osteosarcoma cell growth through the JAK2/STAT3/VEGF signaling pathway.

Authors:  Zhong Lei; Huijie Duan; Tengfei Zhao; Yuxiang Zhang; Guoqi Li; Jiahong Meng; Suzhan Zhang; Weiqi Yan
Journal:  Cell Death Dis       Date:  2018-03-07       Impact factor: 8.469

Review 5.  Parkinson's disease-associated protein Parkin: an unusual player in cancer.

Authors:  Juan Liu; Cen Zhang; Wenwei Hu; Zhaohui Feng
Journal:  Cancer Commun (Lond)       Date:  2018-06-26

6.  Parkin gene mutations are not common, but its epigenetic inactivation is a frequent event and predicts poor survival in advanced breast cancer patients.

Authors:  Khushnuma Wahabi; Ahmad Perwez; Shabeena Kamarudheen; Zafar Iqbal Bhat; Anurag Mehta; M Moshahid A Rizvi
Journal:  BMC Cancer       Date:  2019-08-20       Impact factor: 4.430

7.  PARK2 Suppresses Proliferation and Tumorigenicity in Non-small Cell Lung Cancer.

Authors:  Huijie Duan; Zhong Lei; Fei Xu; Tao Pan; Demin Lu; Peili Ding; Chunpeng Zhu; Chi Pan; Suzhan Zhang
Journal:  Front Oncol       Date:  2019-08-23       Impact factor: 6.244

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.